3-(6-Methyl-3-pyridyl)propionic acid | 118420-23-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-(6-Methyl-3-pyridyl)propionic acid
• 英文别名: 3-(6-Methyl-pyridin-3-yl)propionic acid；3-(6-Methyl-3-pyridinyl)propanoic acid；3-(6-methylpyridin-3-yl)propanoic acid
• CAS: 118420-23-8
• 化学式: C₉H₁₁NO₂
• 分子量: 165.192
• InChiKey: KLZCMDLXAQTIRX-UHFFFAOYSA-N

物化性质

• 熔点：
  114 °C
• 沸点：
  310.4±27.0 °C(Predicted)
• 密度：
  1.156±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(4-diphenyl-methyl-1-piperazinyl)butylamine 、 3-(6-Methyl-3-pyridyl)propionic acid 在 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 以37%的产率得到N-[3-(6-methyl-pyridin-3-yl)propionyl]-4-(4-diphenylmethyl-1-piperazinyl)butylamine
  参考文献：
  名称：

  Acrylamide derivatives as antiallergic agents. 2. Synthesis and structure activity relationships of N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3-(3-pyridyl)acrylamides

  摘要：

  A new series of 3-(3-pyridyl)acrylamides 16, 17, 19, and 26, and 5-(3-pyridyl)-2,4-pentadienamides 20-25 were prepared and evaluated for their antiallergic activity. Several of these compounds exhibited more potent inhibitory activities than the parent compound 1a [(E)-N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3- (3-pyridyl)acrylamide] against the rat passive cutaneous anaphylaxis (PCA) reaction and the enzyme 5-lipoxygenase. Particularly, (E)-N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3- (6-methyl-3-pyridyl)acrylamide (17p) showed an ED50 value of 3.3 mg/kg po in the rat PCA test, which was one-fifth of ketotifen and oxatomide. As compared with ketotifen and oxatomide, compound 17p (AL-3264) possessed a better balance of antiallergic properties due to inhibition of chemical mediator release, inhibition of 5-lipoxygenase, and antagonism of histamine.

  DOI：

  10.1021/jm00123a012
• 作为产物：
  描述：

  反-3(3-吡啶基)烯丙酸 在 palladium on activated carbon 作用下， 以 N-甲基乙酰胺 、 甲醇 为溶剂， 生成 3-(6-Methyl-3-pyridyl)propionic acid
  参考文献：
  名称：

  .omega.-(3-pyridyl)alkenamide derivatives and anti-allergenic

  摘要：

  该公式化合物为：其中X为烷基或--(CR6.dbd.CR7)r--，其中R6为H、烷基或苯基，R7为H、烷基、氰基或苯基，r为1或2；A为烷基或至少有一个双键中断的烷基；R1为H、卤素、烷基、烷氧基、烷基硫基、环烷氧基、环烷硫基、烷氧羰基、羧基、苯基、苯氧基、苯硫基、3-吡啶氧基或3-吡啶硫基；R2为H、羟基、烷酰氧基或烷氧羰氧基，或相邻的R1和R2可结合形成四亚甲基或--CH2OCR8R9O--（R8和R9为烷基）；R3为H、烷基或羟基烷基；R4为H或烷基；R5为苯基、杂环芳基或--(CH2)m--CHR10R11（R10为H或苯基，R11为苯基或吡啶基，m为0至2）；p为0或1；q为2或3；苯基或基团可选择性地被取代，以及其盐，以及制备方法和含有该化合物的药物组合物。所述化合物及其盐主要通过5-脂氧合酶抑制活性、抗组胺活性和/或抑制化学介质释放活性表现出优异的抗过敏活性，对于治疗过敏性疾病具有用处。

  公开号：

  US04778796A1

文献信息

• COMPOUND FOR INCREASING KINASE ACTIVE AND APPLICATION THEREOF
  申请人：Kang Xinshan

  公开号：US20130225587A1

  公开（公告）日：2013-08-29

  The compound of Formula (I), pharmaceutically acceptable salts thereof, solvates thereof, chelates thereof, non-covalent complexes thereof or produgs of compounds mentioned above or the mixture of any form above mentioned are provided. The use of the compounds in manufacturing a medicament for the treatment and/or prevention of diabetes, obesity and related disorders.

  提供Formula (I)的化合物，其药用可接受盐，溶剂化合物，螯合物，非共价复合物或上述化合物的前体，或上述任何形式的混合物。利用这些化合物制造药物，用于治疗和/或预防糖尿病、肥胖和相关疾病。
• [EN] BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES PONTÉS ET LEURS PROCÉDÉS D'UTILISATION
  申请人：MEDIVATION TECHNOLOGIES INC

  公开号：WO2009120720A1

  公开（公告）日：2009-10-01

  This disclosure relates to new compounds that may be used to modulate a histamine receptor in an individual. Novel compounds are described, including new bridged heterocyclic [4,3-b]indole compounds. Pharmaceutical compositions are also provided. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

  这项披露涉及可能用于调节个体组织中组胺受体的新化合物。描述了新的化合物，包括新的桥接杂环[4,3-b]吲哚化合物。还提供了药物组合物。提供了包含这些化合物的药物组合物，以及使用这些化合物在各种治疗应用中的方法，包括治疗认知障碍、精神障碍、神经递质介导的障碍和/或神经元障碍。
• 3-Carbamoyl-2-Pyridone Derivative
  申请人：Ishizuka Natsuki

  公开号：US20080103139A1

  公开（公告）日：2008-05-01

  The present invention provides compounds having an agonistic activity to the cannabinoid receptor, which is represented by the formula (I): wherein R 1 is optionally substituted C1-C8 alkyl and the like; R 2 is C1-C6 alkyl; R 3 is C1-C6 alkyl and the like; or R 2 and R 3 taken together with may form an optionally substituted 5 to 10 membered non-aromatic carbon ring; R 4 is hydrogen and the like; G is a group selected from the groups shown by the formula an the like: wherein R 5 is hydrogen and the like; X 1 is a single bond and the like; X 2 is optionally substituted C1-C8 alkylene that may be replaced by one or two groups of —O—, or —N(R 6 )—, wherein R 6 is hydrogen and the like, and the like; X 3 is a single bond and the like; a pharmaceutically acceptable salt or a solvate thereof, and pharmaceutical compositions, atopic dermatitis treating agents, and anti-pruritus agents, especially anti-pruritus agents for oral used and for external application, which each contains the said compound as an active ingredient.

  本发明提供了具有激动大麻素受体的作用的化合物，其由式（I）表示：其中，R1是可选取的取代的C1-C8烷基等；R2是C1-C6烷基；R3是C1-C6烷基等；或R2和R3共同形成可选取代的5至10个成员的非芳香碳环；R4是氢等；G是由式等所示的基团中选取的基团：其中，R5是氢等；X1是单键等；X2是可选取代的C1-C8烷基，可以被一或两个-O-或-N（R6）-的基团替代，其中R6是氢等；X3是单键等；其药学上可接受的盐或其溶剂，以及制药组合物、治疗特应性皮炎的制剂和抗瘙痒剂，特别是口服和外用的抗瘙痒剂，每种制剂均以所述化合物为活性成分。
• 3-CARBAMOYL-2-PYRIDONE DERIVATIVES
  申请人：ISHIZUKA Natsuki

  公开号：US20120208813A1

  公开（公告）日：2012-08-16

  The present invention provides compounds having an agonistic activity to the cannabinoid receptor, which is represented by the formula (I): wherein R 1 , R 2 , R 3 , R 4 , and G are defined as herein, a pharmaceutically acceptable salt or a solvate thereof, and pharmaceutical compositions, atopic dermatitis treating agents, and anti-pruritus agents, especially anti-pruritus agents for oral used and for external application, which each contains the said compound as an active ingredient.

  本发明提供了具有激动大麻素受体的活性的化合物，该受体由公式（I）表示：其中R1、R2、R3、R4和G如本文所定义，其药学上可接受的盐或溶剂，以及制备该化合物为活性成分的药物组合物、治疗特应性皮炎的药剂和抗瘙痒剂，尤其是用于口服和外用的抗瘙痒剂。
• BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE
  申请人：MEDIVATION TECHNOLOGIES, INC.

  公开号：US20130190303A1

  公开（公告）日：2013-07-25

  This disclosure relates to new compounds that may be used to modulate a histamine receptor in an individual. Novel compounds are described, including new bridged heterocyclic [4,3-b]indole compounds. Pharmaceutical compositions are also provided. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

  本公开涉及可用于调节组织胺受体的新化合物。其中描述了新的桥接杂环[4,3-b]吲哚化合物。还提供了制药组合物，包括含有该化合物的制药组合物。还提供了使用该化合物进行各种治疗应用的方法，包括治疗认知障碍、精神障碍、神经递质介导的障碍和/或神经元障碍。